Business

Mass. Movers

Covidien separates from pharma business

Covidien’s chief executive , Jose E. Almeida, wished success to Mallinckrodt.

Yoon S. BYUN/Globe Staff/File 2012

Covidien’s chief executive , Jose E. Almeida, wished success to Mallinckrodt.

Advertisement

Health care products maker Covidien PLC Monday said it completed the spinoff of its pharmaceuticals business, Mallinckrodt, into a separate publicly traded company. Covidien, which bases its US headquarters in Mansfield, had disclosed the planned spinoff in December 2011. Covidien executives said the separation allows both firms to pursue their own strategies. Mallinckrodt shares, which began trading on Monday, closed down about 3 percent at $43.92

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com